The UK and US have agreed to a important commercial pact that will maintain zero duties on UK drug shipments being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on medicines through the public health system. This pledge ensures that tariffs on these crucial goods will remain at zero for a timeframe of 36 months.
This development is in response to earlier warnings to hike import taxes on patented drug imports, with increases floated as high as one hundred percent.
"This deal with the Britain reinforces the global environment for cutting-edge drugs and establishes much-needed balance to American-British medicine commerce," an announcement said.
Economic Significance
Drugs are one of the the United Kingdom's most significant goods shipped to the US, which is clearly the biggest buyer for leading UK drugmakers.
Export figures reveal that in the year leading up to last September, the UK sold drugs valued at £11.1bn to the US. This value made up 17.4% of British export trade in that timeframe.
"This agreement safeguards jobs, boosts capital expenditure and facilitates the UK to establish itself as a international leader for medical research," a government official commented.
Key UK Commitments
The deal includes several notable commitments from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to double overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum drug companies must return to the NHS to control costs will be capped at fifteen percent. Last year, refunds were more than twenty percent.
Recent Tensions
The pact takes place against a protracted row between the sector and the ministers over medicine costs and approval rates.
The disagreement were exacerbated by claims that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward US facilities.
A senior figure publicly accepted that the NHS must increase expenditure on medicines, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
